A Review on the Update of Combined Hepatocellular Cholangiocarcinoma
- PMID: 31887773
- DOI: 10.1055/s-0039-3402515
A Review on the Update of Combined Hepatocellular Cholangiocarcinoma
Abstract
Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a primary liver tumor with neoplastic components of both hepatocytic and cholangiocytic differentiation. This unique neoplasm is gaining increasing recognition due to the intriguing pathology, tumor biology, and clinical behavior. It also poses challenges in diagnosis, treatment, and research, largely because of its histological and phenotypic diversity that lead to confusion in terminology and classification. There have been efforts attempting to unify the terminology of this neoplasm recently. Advances in investigation in various aspects have also been made. This review aims to update the terminology, classification, and clinical and pathological characteristics of cHCC-CCA.
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
Conflict of interest statement
Both authors have no conflicts of interest to declare.
Similar articles
-
Establishment of two novel organoid lines from patients with combined hepatocellular cholangiocarcinoma.Hum Cell. 2024 Dec 6;38(1):27. doi: 10.1007/s13577-024-01148-w. Hum Cell. 2024. PMID: 39643731
-
Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?Histopathology. 2022 Apr;80(5):859-868. doi: 10.1111/his.14622. Epub 2022 Mar 3. Histopathology. 2022. PMID: 35076959
-
Diagnosis, clinical characteristics, and treatment of combined hepatocellular-cholangiocarcinoma.Jpn J Clin Oncol. 2025 Apr 6;55(4):327-333. doi: 10.1093/jjco/hyaf029. Jpn J Clin Oncol. 2025. PMID: 39936601 Review.
-
Combined hepatocellular-cholangiocarcinoma: An update.J Hepatol. 2021 May;74(5):1212-1224. doi: 10.1016/j.jhep.2021.01.035. Epub 2021 Feb 3. J Hepatol. 2021. PMID: 33545267 Review.
-
Combined hepatocellular carcinoma and cholangiocarcinoma: a case report and review of the literature.Hepatobiliary Pancreat Dis Int. 2007 Dec;6(6):656-9. Hepatobiliary Pancreat Dis Int. 2007. PMID: 18086637
Cited by
-
Morbidity, Prognostic Factors, and Competing Risk Nomogram for Combined Hepatocellular-Cholangiocarcinoma.J Oncol. 2021 Dec 10;2021:3002480. doi: 10.1155/2021/3002480. eCollection 2021. J Oncol. 2021. PMID: 34925507 Free PMC article.
-
SP1 induced long non-coding RNA AGAP2-AS1 promotes cholangiocarcinoma proliferation via silencing of CDKN1A.Mol Med. 2021 Feb 1;27(1):10. doi: 10.1186/s10020-020-00222-x. Mol Med. 2021. PMID: 33522895 Free PMC article.
-
Establishment of two novel organoid lines from patients with combined hepatocellular cholangiocarcinoma.Hum Cell. 2024 Dec 6;38(1):27. doi: 10.1007/s13577-024-01148-w. Hum Cell. 2024. PMID: 39643731
-
A Case of First-line Atezolizumab Plus Bevacizumab Use in Recurrence of Combined Hepatocellular Cholangiocarcinoma After Surgical Resection.J Clin Exp Hepatol. 2024 Sep-Oct;14(5):101430. doi: 10.1016/j.jceh.2024.101430. Epub 2024 Apr 16. J Clin Exp Hepatol. 2024. PMID: 38766623 No abstract available.
-
Albumin-to-Alkaline Phosphatase Ratio is an Independent Prognostic Indicator in Combined Hepatocellular and Cholangiocarcinoma.J Cancer. 2020 Jun 29;11(17):5177-5186. doi: 10.7150/jca.45633. eCollection 2020. J Cancer. 2020. PMID: 32742464 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical